Citadel Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.19M | Sell |
56,400
-46,100
| -45% | -$2.69M | ﹤0.01% | 5148 |
|
|
2025
Q4 | $6.09M | Buy |
102,500
+5,700
| +6% | +$310K | ﹤0.01% | 3975 |
|
|
2025
Q3 | $5.24M | Buy |
96,800
+2,400
| +3% | +$137K | ﹤0.01% | 4279 |
|
|
2025
Q2 | $5.19M | Sell |
94,400
-92,600
| -50% | -$5.45M | ﹤0.01% | 4057 |
|
|
2025
Q1 | $13.2M | Sell |
187,000
-104,200
| -36% | -$7.01M | ﹤0.01% | 2515 |
|
|
2024
Q4 | $19.1M | Buy |
291,200
+31,800
| +12% | +$2.13M | ﹤0.01% | 2199 |
|
|
2024
Q3 | $18.2M | Sell |
259,400
-76,800
| -23% | -$6.42M | ﹤0.01% | 2145 |
|
|
2024
Q2 | $27.7M | Buy |
336,200
+221,100
| +192% | +$18.4M | 0.01% | 1678 |
|
|
2024
Q1 | $10.1M | Buy |
115,100
+16,200
| +16% | +$1.45M | ﹤0.01% | 2952 |
|
|
2023
Q4 | $9.54M | Sell |
98,900
-227,600
| -70% | -$20.1M | ﹤0.01% | 2913 |
|
|
2023
Q3 | $28.9M | Buy |
326,500
+114,000
| +54% | +$10.1M | 0.01% | 1535 |
|
|
2023
Q2 | $18.4M | Buy |
212,500
+21,900
| +11% | +$2.06M | ﹤0.01% | 1972 |
|
|
2023
Q1 | $18.5M | Buy |
190,600
+100,100
| +111% | +$10.4M | ﹤0.01% | 2000 |
|
|
2022
Q4 | $9.37M | Sell |
90,500
-148,200
| -62% | -$13.9M | ﹤0.01% | 2927 |
|
|
2022
Q3 | $20.2M | Sell |
238,700
-18,800
| -7% | -$1.67M | ﹤0.01% | 1866 |
|
|
2022
Q2 | $21.3M | Buy |
257,500
+165,700
| +181% | +$13.2M | 0.01% | 1780 |
|
|
2022
Q1 | $7.08M | Sell |
91,800
-36,700
| -29% | -$3.07M | ﹤0.01% | 3534 |
|
|
2021
Q4 | $11.4M | Sell |
128,500
-180,400
| -58% | -$14.9M | ﹤0.01% | 2860 |
|
|
2021
Q3 | $23.9M | Buy |
308,900
+119,200
| +63% | +$9.4M | 0.01% | 1806 |
|
|
2021
Q2 | $15.8M | Sell |
189,700
-38,200
| -17% | -$3.03M | ﹤0.01% | 2383 |
|
|
2021
Q1 | $17.2M | Buy |
227,900
+21,800
| +11% | +$1.78M | ﹤0.01% | 2157 |
|
|
2020
Q4 | $18.1M | Sell |
206,100
-124,800
| -38% | -$9.89M | ﹤0.01% | 1915 |
|
|
2020
Q3 | $25.2M | Buy |
330,900
+131,500
| +66% | +$13.3M | 0.01% | 1377 |
|
|
2020
Q2 | $24.6M | Buy |
199,400
+74,100
| +59% | +$7.36M | 0.01% | 1322 |
|
|
2020
Q1 | $10.6M | Buy |
125,300
+62,400
| +99% | +$5.38M | ﹤0.01% | 1783 |
|
|
2019
Q4 | $5.32M | Buy |
62,900
+25,300
| +67% | +$1.91M | ﹤0.01% | 3003 |
|
|
2019
Q3 | $2.53M | Sell |
37,600
-72,300
| -66% | -$5.57M | ﹤0.01% | 4113 |
|
|
2019
Q2 | $9.41M | Sell |
109,900
-44,000
| -29% | -$3.76M | ﹤0.01% | 2250 |
|
|
2019
Q1 | $13.7M | Buy |
153,900
+91,100
| +145% | +$8.44M | 0.01% | 1696 |
|
|
2018
Q4 | $5.35M | Sell |
62,800
-42,300
| -40% | -$4.02M | ﹤0.01% | 2682 |
|
|
2018
Q3 | $10.2M | Buy |
105,100
+29,900
| +40% | +$2.98M | ﹤0.01% | 2073 |
|
|
2018
Q2 | $7.08M | Buy |
75,200
+27,200
| +57% | +$2.38M | ﹤0.01% | 2319 |
|
|
2018
Q1 | $3.89M | Sell |
48,000
-9,700
| -17% | -$832K | ﹤0.01% | 2767 |
|
|
2017
Q4 | $5.14M | Buy |
57,700
+20,500
| +55% | +$1.78M | ﹤0.01% | 2450 |
|
|
2017
Q3 | $3.46M | Buy |
37,200
+8,200
| +28% | +$725K | ﹤0.01% | 2728 |
|
|
2017
Q2 | $2.63M | Buy |
29,000
+9,300
| +47% | +$846K | ﹤0.01% | 2818 |
|
|
2017
Q1 | $1.73M | Sell |
19,700
-4,600
| -19% | -$409K | ﹤0.01% | 3232 |
|
|
2016
Q4 | $2.01M | Sell |
24,300
-14,000
| -37% | -$1.2M | ﹤0.01% | 2937 |
|
|
2016
Q3 | $3.54M | Buy |
38,300
+25,000
| +188% | +$2.35M | ﹤0.01% | 2325 |
|
|
2016
Q2 | $1.03M | Sell |
13,300
-300
| -2% | -$25.5K | ﹤0.01% | 3508 |
|
|
2016
Q1 | $1.12M | Sell |
13,600
-4,800
| -26% | -$391K | ﹤0.01% | 3346 |
|
|
2015
Q4 | $1.93M | Sell |
18,400
-9,900
| -35% | -$1.03M | ﹤0.01% | 2782 |
|
|
2015
Q3 | $2.98M | Sell |
28,300
-6,500
| -19% | -$868K | ﹤0.01% | 2473 |
|
|
2015
Q2 | $4.76M | Sell |
34,800
-14,500
| -29% | -$1.8M | ﹤0.01% | 2117 |
|
|
2015
Q1 | $6.14M | Buy |
49,300
+28,500
| +137% | +$3.02M | 0.01% | 1827 |
|
|
2014
Q4 | $1.88M | Buy |
20,800
+2,200
| +12% | +$183K | ﹤0.01% | 2979 |
|
|
2014
Q3 | $1.34M | Sell |
18,600
-11,300
| -38% | -$743K | ﹤0.01% | 3335 |
|
|
2014
Q2 | $1.86M | Sell |
29,900
-5,700
| -16% | -$344K | ﹤0.01% | 2788 |
|
|
2014
Q1 | $2.43M | Sell |
35,600
-8,900
| -20% | -$656K | ﹤0.01% | 2454 |
|
|
2013
Q4 | $3.13M | Buy |
44,500
+12,100
| +37% | +$822K | ﹤0.01% | 2103 |
|
|
2013
Q3 | $2.34M | Sell |
32,400
-40,100
| -55% | -$2.67M | ﹤0.01% | 2268 |
|
|
2013
Q2 | $4.04M | Buy |
+72,500
| New | +$4.52M | 0.01% | 1764 |
|
Other funds holding BMRN
VCM
VPM
Citadel Advisors's BMRN Position: Q1 2026 in Review
Citadel Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 231% in Q1 2026, buying an estimated $184M and bringing the position to 4,512,634 shares worth $255M. The position accounts for 0.04% of the portfolio, ranked #355.
Citadel Advisors first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $263M in Q4 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Citadel Advisors held 4,512,634 shares of BioMarin Pharmaceuticals worth $255M as of Q1 2026.
- Citadel Advisors bought 3,147,943 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $184M.
- BioMarin Pharmaceuticals made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #355 holding.
- Citadel Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citadel Advisors's BioMarin Pharmaceuticals position peaked at $263M in Q4 2020.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.